Free Trial
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

Nabriva Therapeutics logo
$1.42
+1.42 (+473,233.33%)
(As of 07/31/2023)

About Nabriva Therapeutics Stock (NASDAQ:NBRV)

Key Stats

Today's Range
$1.35
$1.90
50-Day Range
N/A
52-Week Range
$1.22
$8.45
Volume
717,200 shs
Average Volume
29,344 shs
Market Capitalization
$45.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Stock News Headlines

Nabriva Therapeutics plc (NBRVF)
DeFi Coin on Verge of Breakout!
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Nabriva Therapeutics PLC NBRVF
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
See More Headlines

NBRV Stock Analysis - Frequently Asked Questions

Nabriva Therapeutics' stock was trading at $0.0003 at the beginning of the year. Since then, NBRV stock has increased by 473,233.3% and is now trading at $1.42.
View the best growth stocks for 2024 here
.

Nabriva Therapeutics plc (NASDAQ:NBRV) posted its earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative net margin of 148.11% and a negative trailing twelve-month return on equity of 365.53%.
Read the conference call transcript
.

Nabriva Therapeutics shares reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nabriva Therapeutics investors own include SCYNEXIS (SCYX), Vaxart (VXRT), VBI Vaccines (VBIV), Acasti Pharma (ACST), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
5/06/2021
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NBRV
Employees
39
Year Founded
N/A

Profitability

Net Income
$-57,190,000.00
Net Margins
-148.11%
Pretax Margin
-144.78%

Debt

Sales & Book Value

Annual Sales
$35.59 million
Book Value
$0.10 per share

Miscellaneous

Free Float
31,493,000
Market Cap
$45.46 million
Optionable
Not Optionable
Beta
1.53

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NBRV) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners